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aim: To evaluate clinical, pathologic and genetic features of desmoplastic melanoma (DM). 
materials & methods: Analysis of all DM records from 1991 to 2015. results: The most 
common location of DMs was the head and neck (69%); median age and follow-up were 
60.5 and 7.3 years, respectively. A familial predisposition for DMs and others malignancies 
was analyzed. Thin Breslow thickness (<4.5 mm) was associated with an intraepidermal 
component or a previous lentigo maligna, whereas high Breslow thickness (>4.5 mm) was 
observed in ‘pure’ DM. Conclusion: DM could progress from an early phase, characterized 
by an intraepidermal component, to late phase, characterized by a dermal nodule. This 
hypothesis correlates with melanoma genetic and NF1 mutation, which could be an early 
event in the progression of DM.
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Desmoplastic melanoma (DM) is a rare subtype of melanoma that shows distinctive clinical and 
histopathologic characteristics [1]. The first description of DM was made by Conley et al. in 1971, 
defining this tumor as, “an invasive melanoma composed of spindle cells and abundant collagen” [1]. 
DM is a rare subtype of malignant melanoma (MM); reports suggest that <4% of all primary cuta-
neous melanomas belong to the desmoplastic type [2–4]. It most frequently occurs in older people on 
the head, neck and upper trunk areas, and is often associated with significant sun damage. DM is 
often described as mainly an amelanotic nodule sometimes associated with a flat pigmented com-
ponent [1,2]. Histologically, Magro et al. described DM as, “a form of melanoma in vertical growth 
phase in which the invasive tumor cells have a spindle morphology and are associated with marked 
stromal response” [3]. The histopathologic relations between DM and lentigo maligna melanoma 
(LMM) are still debated, and there appears to be an almost complete correspondence between the 
morphologic appearance of DM and the vertical growth phase of spindle cell melanoma, as seen in 
LMM. The histopathological classification then subdivides DM into ‘true’ DMs, also named ‘pure’, 
and ‘spindle cell’ melanomas, also named ‘mixed’ [3–6]. The differences between spindle cell DM are 
often subtle because of somewhat overlapping features and difficulties in collagen content quantifi-
cation. One possible solution for this diagnostic dilemma was the introduction of an intermediate 
class (called mixed or combined spindle/DM) [6]. Further pathologic investigations may require 
the use of immunostains for conventional melanocytic markers (i.e., melan-A and HMB-45) and 
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neural crest markers (i.e., S-100 and SOX10), 
for higher diagnostic accuracy [7–11].
Several DNA mutations have been recog-
nized in MM, including BRAF, NRAS, GNAQ, 
KIT and NF1 at genetic analysis. Each of these 
mutated genes has been found to correlate with 
distinct clinical and histopathologic features, 
and anatomic sites. Interestingly, activating 
BRAFV600E mutations, which are reported to 
be present in approximately half of non-DMs, 
are absent in DM, and provide additional 
evidence for a different biology of the tumor 
[12–16]. Recently, some authors reported a high 
incidence of NF1 mutations in DM, suggest-
ing a central role for NF1 in the biology of this 
MM subtype [17,18]. NF1 is a GTPase-activating 
protein whose mutations are correlated to neu-
rofibromatosis type 1 [19,20], but also to the 
development of several neoplasms, such as: 
glioma, neurofibroma, peripheral nerve sheath 
tumors, pheochromocytoma, breast cancer and 
lymphoma [21–23].
DM diagnosis is usually challenging for the 
dermatologist. Dermoscopy could be helpful for 
the identification of melanocytic features and 
the possible recognition of melanoma-associated 
patterns [24]. Other imaging techniques could be 
helpful for the diagnosis and characterization of 
DM. Reflectance confocal microscopy (RCM) is 
a versatile imaging technique of established value 
for accurate diagnosis of many dermatological 
neoplasms and many other skin diseases [25–29]. 
The aim of our single-institution study was to 
examine clinical, pathologic and genetic features 
of DM patients in order to characterize the role 
of their family history and report their clinical 
course.
materials & methods
Our Unit of Pathology provided the complete 
register with names and medical records of 
every patient with a histopathological diagno-
sis of DM for the period 1991–2015. A retro-
spective review was completed on 13 patients 
affected by DM and treated within our Unit of 
Dermatology. The following information was 
collected: patient demographics (sex, age, date of 
diagnosis), family history, pathologic features of 
the DM, treatment and clinical course. DM data 
included: tumor site, Breslow thickness, Clark 
level, mitoses, tumor-infiltrating lymphocytes, 
perineural involvement, vascular involvement, 
regression, ulceration, characterization of DM 
as pure or mixed, American Joint Committee on 
Cancer stage, date of surgical procedure, mar-
gins, clinical lymph node status, lymph node 
procedure, positive lymph nodes, metastasis, 
extensive/recurrence, treatment, follow-up, sur-
vival and diagnosis of nonmelanoma skin cancer. 
In addition, the presence and management of the 
recurrences were detailed. Clinical and dermo-
scopic images were retrieved from the archives 
of the Dermatological Unit. Whenever available, 
RCM images were collected and analyzed. In 
addition, to decipher the amount of desmoplasia 
in each sample, an expert pathologist revised the 
slides present in the archives of the Pathology 
Unit, classifying them as either pure DM or 
mixed DM using the Memorial Sloan–Kettering 
Cancer Center (MSKCC) classification sys-
tem [3–6,9,11]. Melanomas with desmoplastic 
structures (paucicellular atypical spindled mel-
anocytes, dermal fibrosis, lymphocytic aggre-
gates) involving at least 90% of the specimen 
were classified as pure, whereas mixed DM was 
characterized by desmoplasia involving <90% 
but >10% of the melanoma. Surgical resection 
and sentinel lymph node biopsy (SLNB) were 
performed in all cases. Patients with a posi-
tive SLNB were offered complete lymph node 
 dissection (CLND).
results
Thirteen patients met inclusion criteria and were 
included in this study (table 1 & Figures 1–3). Six 
family trees were drawn in order to define the 
possible familial associations with other tumors. 
The analysis revealed a familial clustering of DM 
with several other neoplasms, in particular with 
adenocarcinoma of the prostate (two cases among 
probands and one case among second-degree rela-
tives) and hepatocarcinoma (two cases among 
first-degree relatives). In addition, there was the 
sporadic observation of lymphoma (one case 
among second-degree relatives), laryngeal carci-
noma (one case among second-degree relatives), 
renal cancer (one case among first-degree rela-
tives), lung cancer (one case among one-degree 
and one case among second-degree relatives), 
pancreas adenocarcinoma (one case among first-
degree relatives), brain tumor (one case among 
first-degree relatives), one adenocarcinoma of the 
gastrointestinal system (one among first-degree 
relatives) and three cancer of unknown site (two 
among first- and one among second-degree rela-
tives). One of the families showed the clinical 
criteria for BRCA1/2 mutations because of mul-
tiple breast cancers with early onset and several 
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Figure 1. Clinical pictures of desmoplastic melanoma. Nodular lesions 
with variable morphology and hard consistency. They are mainly located on 
sun-exposed areas of the body (a–D), but rarely can occur on other body 
locations (e).
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uterine carcinomas among relatives. Median 
follow-up was 7.3 years. Our demographic data 
show a male predominance (69%). Median age 
was 75.6 years, the most common primary site 
was the head and neck (69%), and the median 
age of onset was 60.5 years. Median Breslow 
thickness was 5.5 mm and all lesions were at 
least a Clark level III. Vascular involvement was 
absent in all patients; ulceration was present in 
three patients (23%); and 62% of lesions exam-
ined showed perineural invasion. Median mitoses 
were 5 × 10 high-power fields. Regression and 
tumor-infiltrating lymphocytes were present 
in one patient (8%) and in six patients (54%), 
respectively. Histologic subtype was evaluated in 
all patients with nine (69%) classified as pure 
and four (31%) classified as mixed. Some DM 
presented blue-gray blotches, atypical globules, 
gray dots, perifollicular brown hyperpigmenta-
tion and veil. For one pigmented lesion, RCM 
images were available and showed the infiltration 
of pleomorphic and dendritic cells of the infun-
dibular portion of a hair follicle, a typical feature 
of LMM (Figure 2). Other DMs were amelanotic-
ulcerated nodules that showed few dermoscopic 
patterns, in particular, polymorphous atypical 
vessels, and milky-red areas and central ulcera-
tion (Figure 3). For one amelanotic lesion, RCM 
images showed the disarrangement of the 
honeycomb structure, atrophy of the epidermis 
and limited pagetoid amelanotic infiltrations. A 
group of hypomelanotic nodular lesions with a 
peripheral pigmented flat portion presented der-
moscopic features that were intermediate with 
respect to the two previously described proto-
types. The rate of regional metastasis was less 
than expected considering that the patients pre-
sented with primary advanced cutaneous mela-
noma. All patients underwent SLNB. In three 
patients (23%) a positive SLNB was confirmed. 
In those three patients a CLND was performed, 
resulting negative.
Discussion
Our single-institution clinical and pathologic 
evaluation of DM confirms that DM is an 
uncommon type of MM, mainly diagnosed 
in the head and neck regions with distinctive 
clinical behavior and pathologic features, espe-
cially regarding its relationship to LMM and 
NF1 gene aberrations. The diagnosis of DM is 
complex, both from clinical, dermoscopic, RCM 
and histopathologic perspective. Dermoscopic 
characterization and RCM analysis could be cru-
cial in the designation of a diagnostic suspect 
of melanoma, because DM clinically mimics 
other lesions such as neuroma, neurofibroma, 
dermal cysts or squamous cell carcinoma. To 
our knowledge, this is the first description of 
DM with RCM imaging, focusing on the char-
acterization of the different RCM characteristics 
between pure and mixed DM.
Previously described neoplasms associated to 
MM were: renal clear cell carcinoma (associated 
with MITF gene mutations) [30], ovarian can-
cer and breast cancer (associated with BRCA2 
gene mutations) [31], pancreatic cancer and 
ocular melanoma (associated with CDKN2A 
gene mutations) [32] or to the wider neoplastic 
spectrum of the BAP-1 germline mutation [33]. 
Although a familial clustering for several tumors 
was observed in the majority of the DM fami-
lies analyzed, no significant correlations were 
defined. This could probably be explained by 
the small population size, but distinctive famil-
ial associations may be uncovered from a larger 
series in the future.
In the beginning, Conley et al. described the 
DM clinical and histopathologic features, as a 
variant of melanoma likely to recur and present 
aggressive behavior [1]. However, DM studies 
have not confirmed this hypothesis, reporting 
low incidences of nodal involvement and related 
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Figure 2. Desmoplastic melanoma associated to an intraepidermal component. Clinical picture of 
a mixed desmoplastic melanoma. The lesion is located on the scalp, showing a raised and infiltrated 
portion with a peripheral pigmented flat area. Clinically it is characterized by multiple colors, 
asymmetry and irregular borders (a). Dermoscopic image shows blue–gray network and blotches, 
atypical brown globules, gray dots, perifollicular brown hyperpigmentation and veil (B). Reflectance 
confocal microscopy image acquired at 30 μm depth from the skin surface showing the infiltration of 
pleomorphic and dendritic cells of the infundibular portion of a hair follicle (C). Histologically, there 
is a dermal proliferation of spindle cells with nuclear atypia and collagen deposition; an atypical 
intraepithelial melanocytic proliferation is present (D).
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mortality [7–11,34–36]. Recent studies reported 
that DM rates of nodal metastasis range from 
0 to 18.8%; lower rates compared with other 
types of melanoma [2,6,10,34]. In addition, many 
authors suggested that survival of DM patients 
is comparable or better than survival of non-DM 
patients [8–9,36–39]. Even though many stud-
ies support the idea that SLNB is necessary for 
most variants of MM of 1.0 mm thickness or 
more, the need to perform SLNB in DM is still 
debated [17,34–35,38]. In our study, median Breslow 
thickness was 5.5 mm, and a positive SLNB was 
observed in three patients (23%), but CLND 
resulted negative. Such differences in the natural 
history between DM and other MM may raise 
many queries about the management of patients 
with DM. Nevertheless, until there is an agree-
ment on the most effective management of DM 
patients, SLNB should be performed according 
to current standards of care for MM.
The histopathologic classification of DM into 
different subtypes is still a matter of scientific 
debate [3–6]. In detail, the presence of a predomi-
nant spindle cell component with a low collagen 
content of <10% is characteristic of spindle cell 
melanoma, a collagen content of 10–90% is 
indicative of mixed spindle/DM and a collagen 
content superior to 90% is representative of DM. 
Recently, a diagnostic algorithm, which does not 
replace careful histomorphological examination 
and clinicopathological correlation, has been pro-
posed revealing that two markers, melan-A and 
trichrome staining, reach the highest diagnostic 
accuracy [6]. The relationship between LMM 
and DM is debated and several authors observed 
that DM usually presents an LMM component 
in the epidermal portion that overlies the tumor 
body or in the resection margins [3–4,40]. The sig-
nificance of dermal elastosis in LMM has been 
previously analyzed by limited studies [41,42] and 
it is of crucial importance to define if UV dam-
age is the unique agent responsible for the col-
lagen dermal alterations seen in LMM and DM, 
or if elastosis and fibrotic dermal grenz zone, 
observed in these tumors, are the results of a com-
plex interplay between tumor cells and stromal 
microenvironmental factors. As it was previously 
demonstrated, fibroblasts play an important role 
in many tumors, acting as a promoter or a sus-
tainer of epithelial cancerogenesis as for PTCH1-
mutated fibroblasts in Gorlin–Goltz syndrome, 
which were able to induce and promote the 
epithelial basal cell carcinoma development [43]. 
Similarly the fibroblast component of DM can act 
in the extracellular matrix production and secre-
tion of protumor growth factors and cytokines. 
Magro et al. proposed an alternative hypothesis 
regarding the stromal collagenization, in which 
the DM neoplastic cells are dedifferentiated clonal 
melanocytes, which act as facultative fibroblast, 
that is, the tumor population comprised altered 
or dedifferentiated melanocytes with fibroblas-
tic features [3,44–49]. In our series, approximately 
a third of DM were associated with the occur-
rence of an atypical lentiginous intraepidermal 
melanocytic component. In two additional cases 
the diagnosis of the DM was preceded by the 
excision of a recurrent LMM on the same site of 
10.2217/fon-2016-0334
Figure 3. Desmoplastic melanoma not associated to an intraepidermal component. Clinical 
picture of a pure desmoplastic melanoma. The lesion is an amelanotic-ulcerated nodule located 
on the scalp (a). Dermoscopic image shows few dermoscopic pattern, in particular, it is possible 
to identify small telangiectatic vessels, polymorphous atypical vessels, milky-red areas and central 
ulceration (B). Reflectance confocal microscopy image acquired at 30 μm depth from the skin surface 
shows the disarrangement of the honeycomb structure, atrophy and disarranged epidermis (C). 
The invasive tumor cells, have spindle morphology, are devoid of pigment and are associated with a 
desmoplastic stromal response (D).
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the lesion. Our data are intriguing because they 
strengthen many correlations between DM and 
LMM. In the past, some authors described the 
similarities between DM and LMM, suggesting 
that DM can be categorized into two subtypes: 
true DMs and spindle cell melanomas, the latter 
being consistent with the vertical invasive com-
ponent of LMM [3,40]. These observations were 
centered largely on the high incidence of tumor 
on sun-damaged skin, in elderly patients, in the 
head and neck area, and because the junction 
aspect of most DM is indistinguishable from the 
vertical growth phase of LMM [5]. In further stud-
ies, it was shown that the magnitude and degree 
of the intraepidermal melanocytic component 
decreased in thicker tumors and that the group 
of DM, which exhibited a connection between 
dermal and epidermal parts, was considerably 
thinner than the melanomas that had a collagen-
free zone between the two portions [4,38]. Our 
data, in accordance with the previous analysis by 
Carlson et al. [4,50], show that a low Breslow thick-
ness of the DMs (<4.5 mm) is associated with 
the presence of an intraepidermal component or 
a history of previous LMM excision, whereas a 
high Breslow thickness (>4.5 mm) is mainly seen 
in ‘pure’ DM. In our opinion, this observation is 
of fundamental value and could lead to a unify-
ing concept of DM, suggesting that the biological 
behavior of these neoplasms could progress from 
an early phase, that is characterized by the pres-
ence of an increased intraepidermal component 
and a thin/inconsistent dermal component, to a 
late phase, that is characterized by the absence of 
the intraepidermal proliferation, probably because 
of advanced regression, and a thick dermal des-
moplastic component. In accordance with this 
hypothesis, in the first type of lesions (‘early’ 
DM), dermoscopy and RCM analysis showed 
the presence of lentigo maligna-like features. In 
detail, dermoscopic images showed rhomboid 
structures, brown circles around hair follicles, gray 
dots and blue-white regression; RCM showed the 
presence of atypical dendritic cells in the epider-
mis and infiltrating the hair follicle, disarrange-
ment of the architecture and atypical cells at the 
dermal epidermal junction. In the second type 
of lesions (‘late’ DM), mainly ulceration and 
amelanotic melanoma features were observed. In 
detail, dermoscopic images showed polymorphic 
vessels, milky-red areas, erosion and ulceration, 
while RCM showed limited pagetoid hypore-
fractive cells, epidermal atrophy and compact 
collagen bundles at the dermal epidermal junc-
tion. Our morphological/biological hypothesis 
correlates well with the recent understandings in 
the field of melanoma genetics, which have not 
identified main genetic differences among DM 
patients, whether they are considered pure DMs 
or mixed melanomas, according to the classifica-
tion suggested by Magro et al. [3]. From a genetic 
point of view, DMs do not harbor BRAF, NRAS, 
GNAQ, GNA11 and KIT mutations. Instead, in 
>90% of cases, they are characterized by NF1 
gene mutations, as was previously demonstrated 
by Wiesner et al. [18]. NF1 is a GTPase-activating 
protein considered to be a suppressed tumor 
that causes the neurofibromatosis syndrome, an 
increase in collagen production by fibroblast and 
the development of neurofibroma, peripheral 
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nerve sheath tumors, glioma, lymphoma, breast 
cancer, pheochromocytoma, melanoma, lentigi-
nous melanocytic nevi, melanocytic hyperplasia 
and lentigo simplex [19–20,51–53]. The important 
roles of NF1 in the development of melanocytic 
lentiginous proliferations, melanomagenesis and 
collagen production, are important tiles in the 
understanding of the DM mosaic. Altered mel-
anocytic activity, in terms of metabolism, pro-
liferation or differentiation, are evident because 
the presence of multiple café-au-lait macules and 
iris hamartomas of melanocytic origin (Lish nod-
ules) is a major feature of the neurofibromatosis 
type 1 syndrome. Additionally, there are evidence 
and reports of a possible association between 
NF1 mutations and conjunctival melanoma or 
DM [54–57].
In our view, the loss of NF1 could be an early 
event that may explain the natural evolution of 
DM: from an early melanocytic intraepidermal 
tumor with a lentiginous-pigmented component, 
to a deep tumor core that invades the dermis, 
increases the stromal collagenous matrix and 
destroys the superficial intraepidermal compo-
nent by regressive phenomena. The weakness of 
our study is the relatively small size of the sample.
Conclusion
The results of our study can be summarized as 
follows: first, several relationships exist between 
DM and LMM, in particular, a subset of LMM 
can constitute the early phase of DM, which are 
characterized by a conspicuous intraepidermal 
component and a thin dermal component. In our 
view, the early phase can evolve into a late phase, 
characterized by a thick dermal desmoplastic 
component, in the absence of the intraepidermal 
proliferation. On the basis of this evidence, we 
suggest a unifying concept of DM that overcomes 
the histopathologic subclassification into ‘true’ 
and ‘spindle cell’ DM. As a second key point we 
highlight the crucial role of tumoral stroma in 
order to define a DM definition: the fibroblas-
tic component is crucial in order to define the 
desmoplastic behavior of DM. Additionally, the 
etiopathogenesis of DM-associated stromal colla-
genization can share the same genetic background 
of malignant melanocytic neoplastic progression. 
Further clinical evaluation based on more wide 
DM series will be able to shed light on the poten-
tial familial predisposition associated with the 
pathogenesis of this rare tumor.
A potential actor of these phenomena could be 
the NF1 aberrations, which have been identified 
in both DM and LMM. At present, in addition 
to NF1 sequencing, the adoption of trichromic 
staining procedures specific for fibroblastic com-
ponents and immunohistochemical analysis of 
the samples could be useful. The third point of 
our conclusion regards the application of mod-
ern imaging techniques such as dermoscopy and 
reflectance confocal microscopy. They represent 
important tools for the preliminary diagnosis of 
DM: in detail the recognition of LMM-like fea-
tures, such as the presence of dendritic atypical 
infundibular invasion of pagetoid cells, allows the 
differentiation of ‘early-phase’ DM, from ‘late-
phase’ DM.
exeCutive summary
 ●  Desmoplastic melanoma (DM) is a rare subtype of melanoma that shows distinctive clinical, histopathologic and 
genetic characteristics.
 ●  The relationships between DM and lentigo maligna melanoma (LMM) is of key value, because approximately a third of 
DM are associated with an atypical lentiginous intraepidermal melanocytic component and the diagnosis of the DM is 
rarely preceded by the excision of an LMM.
 ●  A subset of LMM, which is characterized by a conspicuous intraepidermal component and a thin dermal component, 
should be considered in the early phase of DM.
 ●  Late-phase DM is characterized by a thick dermal desmoplastic component, in the absence of the intraepidermal 
proliferation.
 ●  A familial clustering of several different tumors is described, but no specific correlations were identified.
 ●  The fibroblastic component is crucial for the potential of the DM, and a potential cause of these phenomena could be 
NF1 aberrations, which were identified in both DM and LMM.
 ●  Modern imaging techniques such as dermoscopy and reflectance confocal microscopy represent important tools for 
the preliminary diagnosis of DM: in detail the recognition of LMM-like feature, like the presence of dendritic atypical 
infundibular invasion of pagetoid cells, allows the differentiation of ‘early-phase’ DM, from ‘late-phase’ DM.
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